过去几年,诺和诺德(Novo Nordisk)和礼来(Eli Lilly)一直在GLP-1注射剂领域展开竞争,如今,两家公司正将战场转向口服药。尽管诺和诺德在口服减重药的上市节奏上略占先机,但两家公司2月12日均披露了新的投资计划,以加速各自产品的全球推广。诺和诺德的口服 Wegovy(司美格鲁肽)今年 1 月在美国上市后迅速放量,上市首月销量便十分可观。根据最新调查,许多患者因害怕注射而更倾向于...
Source Link过去几年,诺和诺德(Novo Nordisk)和礼来(Eli Lilly)一直在GLP-1注射剂领域展开竞争,如今,两家公司正将战场转向口服药。尽管诺和诺德在口服减重药的上市节奏上略占先机,但两家公司2月12日均披露了新的投资计划,以加速各自产品的全球推广。诺和诺德的口服 Wegovy(司美格鲁肽)今年 1 月在美国上市后迅速放量,上市首月销量便十分可观。根据最新调查,许多患者因害怕注射而更倾向于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.